Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report) shares traded down 4.8% during trading on Monday . The stock traded as low as $21.50 and last traded at $21.83. 224,694 shares traded hands during trading, an increase of 348% from the average session volume of 50,104 shares. The stock had previously closed at $22.92.
Neoleukin Therapeutics Stock Down 8.8%
The firm has a 50 day simple moving average of $14.67 and a two-hundred day simple moving average of $17.59. The stock has a market capitalization of $187.11 million, a P/E ratio of -6.40 and a beta of 1.11.
Neoleukin Therapeutics Company Profile
(
Get Free Report)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Read More
Before you consider Neoleukin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neoleukin Therapeutics wasn't on the list.
While Neoleukin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
